Otorhinolaringology Department, Fundación Santa Fe de Bogotá, Bogotá, Colombia.
Pneumology Department Fundación Neumológica Colombiana, Bogotá, Colombia.
NPJ Prim Care Respir Med. 2022 Oct 29;32(1):47. doi: 10.1038/s41533-022-00313-8.
Allergic rhinitis and asthma are common diseases that frequently coexist, referred to as unified airway disease. There is currently no validated scale in Spanish, which allows simultaneous evaluation of both conditions. A translation from Portuguese to Spanish was therefore performed. It was administered to 120 patients aged between 18 and 70 years whose native language was Spanish and presented a diagnosis of allergic rhinitis and asthma. The reliability, validity and sensitivity to instrument change validations were carried out, as well as the values of minimally relevant clinical differences. Reliability was evaluated using Cronbach´s alpha test on CARAT-global: 0.83 [IC 95% 0.79-0.88]; test and retest evaluation was done with Pearson´s correlation coefficient: 0.6 [IC 95% 0.32-0.77] and the standard error of measurement 3.5 (p < 0.005). A confirmatory factor analysis was performed corroborating two factors. Correlation coefficients were not high in the longitudinal validation. Concurrent validity showed an acceptable correlation between CARAT10 asthma ACQ5 and low between allergic rhinitis-VAS. There was a milestone of the controlled disease in the discriminant validity of CARAT10 rhinitis ≥ 8 mean an adequate control, CARAT10-asthma > 16 In this case, CARAT10-asthma value < 16 are interpreted as an inadequate or partial control and values ≥ 16 mean an adequate control and CARAT10-global ≥ 18, patients evaluated with CARAT10 with a result ≥ 18, which would be a patient with both conditions controlled. The minimally relevant clinically important average difference found in the CARAT10 scale was 3.25 (SD 3.77). The CARAT10 scale in Spanish is a standardised, reliable and valid evaluation method on patients with unified airway disease.
变应性鼻炎和哮喘是常见的疾病,常同时存在,被称为联合气道疾病。目前在西班牙语中没有经过验证的量表,可以同时评估这两种疾病。因此,我们进行了从葡萄牙语到西班牙语的翻译。该量表被用于 120 名年龄在 18 至 70 岁之间、母语为西班牙语且被诊断为变应性鼻炎和哮喘的患者。我们对其进行了信度、效度和仪器变化敏感性验证,以及最小临床相关差异值的评估。使用 Cronbach´alpha 测试对 CARAT-global 进行信度评估:0.83 [95%置信区间 0.79-0.88];采用 Pearson 相关系数进行测试-再测试评估:0.6 [95%置信区间 0.32-0.77],测量标准误差为 3.5(p<0.005)。进行了验证性因子分析,证实了两个因素。纵向验证中的相关系数不高。同时效度显示 CARAT10 哮喘 ACQ5 之间具有良好的相关性,而变应性鼻炎-VAS 之间相关性较差。在疾病控制的判别效度方面,CARAT10 鼻炎≥8 意味着疾病得到了充分控制,而 CARAT10-哮喘>16 则意味着疾病控制不足或部分控制。在这种情况下,CARAT10-哮喘值<16 被解释为控制不足或部分控制,而值≥16 意味着控制充分,CARAT10-global≥18,用 CARAT10 评估的患者结果≥18,意味着这两种疾病都得到了控制。在 CARAT10 量表中发现的最小临床相关重要平均差异为 3.25(SD 3.77)。西班牙语版的 CARAT10 量表是一种针对联合气道疾病患者的标准化、可靠且有效的评估方法。